SHORTAGE OF HIGH-COST MEDICATIONS: AN ANALYSIS OF AVAILABILITY AND INTERRUPTION OF ACCESS IN TERESINA, PI

Abstract

Medication shortages in the Brazilian Unified Health System (SUS) expose the population to treatment interruptions, worsening of diseases, and increased costs. This study evaluated the frequency of shortages of medicines from the Specialized Component of Pharmaceutical Care (CEAF) in Teresina, Piauí, and discussed their possible consequences for users. A descriptive, qualitative-quantitative, longitudinal study was conducted, with 28 queries to the state Pharmaceutical Care portal between September 30, 2025, and September 28, 2026. Data were organized in Microsoft Excel and presented in graphs. Thirteen presentations had at least one shortage. Rivastigmine 2 mg (bottle) was absent in all queries and for 363 days; mesalazine 250 mg, in 96.4% of them and for 343 days. Antidementia drugs, hematological agents, intestinal anti-inflammatory drugs, and immunosuppressants were the most affected classes. It was concluded that shortages were recurrent and long-lasting, affected continuous treatments, and may compromise therapeutic adherence, costs, and the peace of mind of patients and families. Strengthening stock monitoring, planning purchases in advance, and informing users are recommended.